○Haw-Ming Huang1, Shih-Kai Lin1, Kan-Shin Fan2, Sheng-Wei Feng1 (1. Sch. Dent., Taipei Med. Univ., 2. Dent. Dep., En-Chu-Kong Hospit.)
Session information
Interdisciplinary Session
[27ISP] Interdisciplinary Session Poster: Antibody therapeutics/Immunology
Mon. Mar 27, 2023 9:00 AM - 5:50 PM [Room P4] Institute for the Advancement of Higher Education: Main Hall Entrance (Bldg. N: 1F)
Discussion time: 15:10-15:50
○Hsuan-Yu Lai1, Liang-Kai Huang2, Haw-Ming Huang1 (1. Sch. Dent., Taipei Med. Univ., 2. Sch. Biom. Eng., Taipei Med. Univ.)
○Mo-Chiu Hsu1, Li-Fu Chen2, Haw-Ming Huang2 (1. Sch. Biom. Eng., Taipei Med. Univ., 2. Sch. Dent., Taipei Med. Univ.)
○Yi-Fei He1, Haw-Ming Huang1 (1. Sch. Dent., Taipei Med. Univ.)
Withdrawn
Withdrawn
○Hsuan-Wei Chen1, Hung-Chieh Wu2, Haw-Ming Huang3 (1. Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical Univ., 2. Master program in school of dentistry, Taipei Medical Univ., 3. Graduate Institute of Biomedical Optomechatronics, Taipei Medical Univ.)
○Kuan-Yu Liu1, I-Pei Kuo1,2, Po-Tsang Lee1, Chia-Jung Lee3,4,5 (1. Department of Aquaculture, National Taiwan Ocean Univ., 2. Freshwater Aquaculture Research Center, Fisheries Research Institute, Council of Agriculture, 3. PhD Program in Clinical Drug Development of Herbal Medicine, Taipei Med. Univ., 4. Grad. Inst. Pharm., Taipei Med. Univ., 5. Traditional Herbal Medicine Research Center, Taipei Med. Univ. Hospital)
○Kengo Hanaya1, Yuki Morimi1, Kazuaki Taguchi1, Kazuaki Matsumoto1, Shuhei Higashibayashi1, Takeshi Sugai1 (1. Faculty of Pharmacy, Keio University)
○Rika Takasugi1, Yutaka Matsuda2, Kei Yamada1, Tomohiro Fujii1, Takuya Seki1, Yusuke Iwai1, Akira Chiba1, Tatsuya Okuzumi1 (1. Ajinomoto Co., Inc., 2. Ajinomoto Bio-Pharma Services)
○Tetsuya Kadonosono1, Yutaka Saito2, Ning Lin1, Shinae Kondoh1 (1. Tokyo Tech, 2. AIST)
○Takamitsu Kohzuma1, Takahide Yamaguchi1, Attila Taborosi1, Seiji Mori1 (1. Grad. Sch. Col. Sci. Engi., Ibaraki Univ.)
○Keisuke Fukazawa1, Sachiko Shindo1, Makiko Ichiki1, Futoshi Sato1, Tatsuya Ezaki1 (1. Nihon Waters)
○Takeshi Fuchigami1, Tsukasa Kosugi1,2, Yusuke Miyanari3, Ayako Tagawa3, Masayuki Munekane1, Kenji Mishiro4, Sakura Yoshida2, Akira Toriba2, Morio Nakayama2, Kazuma Ogawa1,4 (1. Grad. Sch. Pharm., Kanazawa Univ., 2. Grad. Sch. Biomed. Sci., Nagasaki Univ., 3. WPI-NanoLSI, Kanazawa Univ., 4. InFiniti., Kanazawa Univ.)
○Takehiro Mukae1, Kyoko Yoshii1, Isao Oishi1 (1. AIST)
○Takumi Iwasawa1,2, Noriaki Iwao2,3, Kazunori Kato1,4, Chikao Morimoto5 (1. Dept. Biomed. Eng., Grad. Sch. Sci. Eng., Toyo Univ.,, 2. Shizuoka Med. Rese. Center for Disaster., Juntendo Univ., 3. Dept. Hematology, Shizuoka Hosp., Juntendo Univ., 4. Atopy Rese. Center, Juntendo Univ., 5. Dept. of Thera. Develop. & Innova. for Immune Disor. & Cancers, Juntendo Univ.)
[27ISP-17 (26P2-pm2-006)] Oridonin modulates cytotoxic ability of NK cells against Lung cancer cells
○Chuan-Hsin Chang1 (1. Chang Gung University of Science and Technology, Taoyuan 333, Taiwan)
○Riko Kobayashi1, Rina Kawabata1, Fumiaki Sato1, Yoshinori Kato1, Makoto Tsuiji1, Teruaki Oku1 (1. Hoshi Univ.)
○Rina Kawabata1, Riko Kobayashi1, Makoto Tsuiji1, Yoshinori Kato1, Teruaki Oku1 (1. Hoshi Univ.)
○Airi Kubota1, Tomohiro Sato1, Junnosuke Sato1, Teruaki Oku1, Makoto Tsuiji1 (1. Hoshi Univ. Sch. Pharm. & Pharm. Sci.)
○Honoka Fujihira1, Miyako Hoshi1, Kento Takahashi1, Natsuki Kodachi1, Yutaka Tatano2, Takuya Ogawa1, Hideki Yagi1 (1. International University of Health and Welfare, School of Pharmacy , 2. International University of Health and Welfare, School of Pharmacy at Fukuoka)
○Aya YOKOTA-NAKATSUMA1, Ka-Min Kim1, Shoko Nagata1, Yoshiharu Ohoka1 (1. Kagawa Sch. Pharm. Sci., Tokushima Bunri Univ.)
○Ren Shimazaki1, Daisuke Yamanaka1, Yoshiyuki Adachi1 (1. Tokyo Univ. Pharm. Life Sci.)
○Zirui Zeng1, Yasuhiro Yoshida1 (1. University of Occupational and Environmental Health, Japan.)
○Yuki Mochida1, Tao Yang1, Xueying Liu1, Hiroaki Kinoh1, Horacio Cabral2, Kazunori Kataoka1 (1. iCONM, Kawasaki Inst. Ind. Promotion, 2. Grad. Sch. Eng., The Univ. of Tokyo)
○Yoshirou Kimura1 (1. MOLSIS Inc.)
○Hiromi Hagiwara1, Takafumi Nakayama2, Hiroya Hashimoto1, Shigeru Kusumoto3, Hidekatsu Fukuta1, Takeshi Kamiya1, Shinsuke Iida3 (1. ncu.clinical trial, 2. ncu.cardiology, 3. ncu.hematology)
○Sena Kamesawa1, Mizuki Ogawa1, Shosei Kai2, Yoshiki Funakoshi2, Takashi Sato1, Yoshihiro Kobashigawa1, Hiroshi Morioka1 (1. Grad. Sch. Pharm. Sci., Kumamoto Univ., 2. Sch. Pharm. Kumamoto Univ.)
○Takashi Matsumoto1, Akimi Sato2, Yoshitaka Kameyama2, Takuma Kozono2, Takashi Tonozuka2, Takashi Sato1, Tomokazu Hasegawa1, Hiroyuki Kanda1, Atsushi Nishikawa2 (1. Rigaku Corporation, 2. Graduate School of Agriculture, Tokyo University of Agriculture and Technology)
○Masaki Takeara1, Momoka Osono1, Sayaka Seki1, Yui Shimizu2, Satoshi Hosoya2, Yoshitaka Tanaka2, Hideki Yagi1 (1. International University of Health and Welfare, School of Pharmacy, 2. Nissui Pharmaceutical Co., Ltd.)